Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Which Bisphosphante drug did you take?

Date you started taking this drug:

Date you stopped taking this drug:

Were you diagnosed with Osteonecrosis of the Jawbone (ONJ)?

Did you suffer a femur fracture:

Please describe your injuries:

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Bisphosphonates Side Effects Lawsuits | Side Effects: Femur Fractures, Thigh Fractures, Osteonecrosis of the Jaw,  Dead Jaw Syndrome, Esophageal Cancer,  Fractures, Atrial Fibrillation, Severe Musculoskeletal Pain

Bisphosphonates Drugs are Meant to Fight Bone Loss,
but They May Cause Broken Bones, Bone Disease Instead

Bisphosphonates Drugs are Meant to Fight Bone Loss, but They May Cause Broken Bones, Bone Disease Instead

Bisphosphonates Drugs are Meant to Fight Bone Loss, but They May Cause Broken Bones, Bone Disease Instead

Bisphosphonates are a class of drugs used to fight bone loss that occurs with osteoporosis. These medications are often prescribed to post-menopausal women with osteoporosis, but they are also prescribed for Paget’s disease and to cancer patients for the prevention of bone fractures. Bisphosphonates can be taken orally, or intravenously. Oral bisphosphonates include Actonel, Boniva, Didronel, Fosamax and Skelid. Aredia, Bonefos and Zometa are all examples of intravenous bisphosphonates.

Throughout the years, these drugs have been linked to the following side effects:

  • Femur fractures (thigh breaks)
  • Esophageal cancer
  • Osteonecrosis of the jaw/Dead Jaw Syndrome
  • Atrial fibrillation
  • Severe musculoskeletal pain

Osteoporosis Drugs and Atypical Femur (Thighbone) Breaks

Bisphosphonates are supposed to fight the effects of bone loss, but major side effects are atypical femur fractures. An atypical femur fracture is when your thighbone, the longest bone of the body, breaks during a normal activity, such as getting up or walking. It is a severe, painful injury potentially caused by the drug mechanism of bisphosphonates. Many lawsuits have been filed over femur fractures allegedly caused by drugs such as Fosamax.

In 2010, the U.S. Food and Drug Administration (FDA) revised the safety label on Fosamax and other bisphosphonate drugs to warn that they can increase the risk of atypical thigh breaks. In May 2012, the FDA also published a review in the New England Journal of Medicine about this class of medication, stating that there is not much evidence to support using bisphosphonates for longer than five years. Another study, published in the June 2012 issue of the Archives of Internal Medicine, looked at the issue by comparing atypical femur fractures to “classic” fractures. The researchers found that 82 percent of the patients with atypical fractures had taken a bisphosphonate drug. These data strongly suggest that bisphosphonate medications do the opposite of what they are intended; instead of preventing bone breaks, drugs like Fosamax could be causing them.

Dead Jaw Syndrome Linked to Bisphosphonate Use

Osteonecrosis of the jaw (ONJ), also known as Dead Jaw Syndrome, is a painful, disfiguring bone condition linked to the use of bisphosphonates. According to the Mayo Clinic, ONJ is likely caused by a bisphosphonate when there is an area of exposed bone in the maxillofacial region that doesn’t heal within eight weeks (identifiable by a health care provider) in a patient who received or has been exposed to a bisphosphonate who has not had radiation therapy. The Mayo Clinic also reports that the highest risk of bisphosphonate-linked jaw necrosis appears to be with intravenous zoledronic acid, sold under the names Zometa, Zomera, Aclasta and Reclast.

Symptoms of ONJ include:

  • Jaw pain
  • Swelling of the gums
  • Loose teeth
  • Drainage
  • Exposed jaw bone
  • Numbness
  • Feeling of heaviness in the jaw

Other Bisphosphonate Side Effects: Heart Problems, Cancer and Muscle Pain

Bisphosphonate drugs have also been linked to a variety of other serious side effects, including heart problems, cancer and musculoskeletal pain.

Bisphosphonates were tied to heart risks in 2007, when the New England Journal of Medicine found that these drugs could increase the chances of developing an abnormal heart rhythm in older women. The following year, another study conducted by researchers at the University of Washington found that taking Fosamax might double the risk of atrial fibrillation. Atrial fibrillation is an irregular heart rhythm that leads to fatigue, dizziness and fainting.

In January 2008, the FDA warned that these medications were associated with severe and sometimes debilitating pain in the bones, joints and muscle (musculoskeletal pain). The agency said at the time that this pain might appear within days, months or years of starting bisphosphonate therapy.

Bisphosphonates may also be tied to cancer of the esophagus, according to a study published in the British Medical Journal in September 2010. The study, which analyzed data from 90,000 people over the course of eight years, found that the risk of esophageal cancer was doubled in those who were prescribed an oral bisphosphonate for five years. Previously, the FDA has also reported a link to esophageal cancer between 1995 and 2008.

Need Legal Help Regarding Bisphosphantes Side Effects?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).



BisphosphonatesRSS Feed

Increased Risk of Atypical Hip Fractures Associated with Bisphosphonate Use

Sep 23, 2015
Women with osteoporosis who take bisphosphonate drugs to prevent fractures have an increased risk of atypical hip fractures, new research finds. Javier Gorricho-Mendívil conducted the research for his PhD thesis at the NUP/UPNA-Public University of Navarre (Spain), MedicalXpress reports. According to Gorricho-Mendívil, hip fracture is the “most common cause" of admission to hospital trauma and orthopaedics departments. Hip fractures are associated with a high rate of...

In Fosamax Trial Opening Statements Merck Charged with Overlooking Problems Linked to the Drug

Apr 10, 2013
Opening statements were made yesterday in a New Jersey courtroom during a new trial over claims that Merck & Co.’s osteoporosis drug Fosamax makes patients more susceptible to thigh fractures. This case is one of over 3,300 pending cases alleging that Merck’s Fosamax caused so-called atypical femur fractures. The plaintiff, Bernadette Glynn, 59, took Fosamax for more than six years before suffering a femur fracture while bending over to pick something up. These so-called...

New Lawsuit Alleging Fosamax Causes Broken Bones to Commence

Apr 4, 2013
A new trial claiming Merck & Co. had hid risks that its osteoporosis drug Fosamax could cause femur fractures is scheduled to start next week.  This trial, the second of more than 3,300 lawsuits alleging Fosamax (alendronate) had caused broken legs, will begin on April 9 in federal court in Trenton, New Jersey, Bloomberg News reports. The first trial ended in a mistrial last month, after the plaintiff suffered a health problem unrelated to Fosamax use, according to a statement on...

New Lawsuit Alleges that Fosamax Caused Femur Fractures in Both Thighs

Sep 18, 2012 | Parker Waichman LLP
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Fosamax caused a femur fracture. The suit was filed on August 30th in the Superior Court of New Jersey Law Division, Atlantic County (Docket No. ATL-L-6104-12 MT). Merck Sharp & Dohme Corp. and Merck & Co., Inc. have been named as Defendants. According to the Complaint, the Plaintiff began taking Fosamax in October 2000. Thereafter, she...

Bisphosphonates, Dental Procedures Not a Good Combo for Some Cancer Patients

Sep 13, 2012 | Parker Waichman LLP
New research suggests that people taking bisphosphonate drugs in the treatment of cancers multiple myeloma or Waldenstrom's macroglobulinemia are more likely to suffer osteonecrosis of the jaw (ONJ) after they undergo a dental procedure.  According to a report on a new study from scientists at Ospedale Nuovo Regina Margherita in Rome, Italy, nearly 80 percent of the cases of ONJ observed as part of the study were among people who had recently undergone a dental surgery,...

More Bisphosphonates News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo